ENXTPA:ABVXBiotechs
Abivax (ENXTPA:ABVX) Stock May Look Expensive Despite Leadership Appointments
ABIVAX Société Anonyme has delivered a very large three year return, yet its valuation checks and current pricing suggest a more mixed picture, with the stock screening as expensive on market multiples rather than a straightforward bargain.
Over the past three years, ABIVAX Société Anonyme has produced a very large total return for shareholders, which raises the bar for what future performance needs to justify from here.
Recent leadership appointments ahead of a planned U.S. New Drug...